TG Therapeutics TGTX Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:DeferredRevenueNoncurrent.
The official record: TG Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about TG Therapeutics's deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is TG Therapeutics's deferred revenue?
- TG Therapeutics (TGTX) reported deferred revenue of $6.86M in Q1 2026.
- How has TG Therapeutics's deferred revenue changed year-over-year?
- TG Therapeutics's deferred revenue increased by 4.0% year-over-year, from $6.6M to $6.86M.
- What is the long-term trend for TG Therapeutics's deferred revenue?
- Over 5 years (2020 to 2025), TG Therapeutics's deferred revenue has grown at a 70.6% compound annual growth rate (CAGR), from $610K to $8.81M.
- What does deferred revenue mean?
- Cash received from customers for work that has not been completed yet.
- How do you interpret deferred revenue?
- An increase is generally a positive signal, indicating strong future revenue potential and customer commitment.
- How does deferred revenue compare across companies?
- Deferred revenue is common in industries with subscription models or long-term service contracts, including certain biotech licensing agreements.